The Manager and its multidisciplinary investment professionals have had substantial experience building businesses. They have a proven history of successfully working with companies in the life science sector in order to add value and achieve investor returns.

Principals of the Manager are associated with the following fund:

IB Australian Bioscience Fund I:

Principals involved - Matt McNamara, Jeremy Curnock Cook, Darren Grubb, Stewart Washer, Nicholas Draeger

• $41.8M FUM.
• $20.5M Capital on Return/Distributions in first 2 years.
• Fund Closed to New Committed Capital June 2010.
• $1 units reached >$2 (60% annual IRR) in the first 30 months since launch (July 2008).

Principals of the Manager have been associated with the following funds:

International Biotechnology Trust (Rothschild):

Principal involved - Jeremy Curnock Cook

• 44% annual IRR (1994-2000).
• NAV growth £77m to £349m.

Biotechnology Investments Limited (Rothschild):

Principal involved - Jeremy Curnock Cook

• 22% annual IRR (1987-2000).
• NAV growth US$150m to US$600m (1987-2000).

Australian Bioscience Trust (Rothschild):

Principal involved - Jeremy Curnock Cook

• A$45 million dedicated life science fund for Australian market.
• Now managed by GBS Venture Partners Ltd.

BB Biotech:

Principal involved: Nora Frey

• 306% over 3 years (1998-2000).
• Public & Private investments with AUM up to CHF 4 bn

Adamant Biomedical:

Principals involved - Nora Frey & Nicholas Draeger

• Over CHF1bn AUM.
• Lacuna SICAV - AdamantAsia Pacific Health fund (Mar 2006- Dec 2007) 25% (vs Bloomberg Active Index 8.3%).
• Geographic coverage for investments included India, Singapore, Japan, South Korea, Australia, China, Taiwan, and Thailand.